Phillip Mertz
Director/Board Member bei ALPHA COGNITION INC.
Vermögen: 728 377 $ am 31.03.2024
Profil
Phillip P.
Mertz is the founder of Secure Open Solutions.
He is currently the Chief Executive Officer at Subtle Technologies and the Director at Alpha Cognition, Inc. He previously worked as a Director at Alpha Cognition, Inc. Mr. Mertz received his undergraduate degree from Harvard University in 2006.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ALPHA COGNITION INC
1,43% | 29.08.2023 | 1 255 822 ( 1,43% ) | 728 377 $ | 31.03.2024 |
Aktive Positionen von Phillip Mertz
| Unternehmen | Position | Beginn |
|---|---|---|
| ALPHA COGNITION INC. | Director/Board Member | 22.03.2021 |
Ehemalige bekannte Positionen von Phillip Mertz
| Unternehmen | Position | Ende |
|---|---|---|
Alpha Cognition, Inc. /old/
 Alpha Cognition, Inc. /old/ Pharmaceuticals: MajorHealth Technology Alpha Cognition, Inc. engages in operation of a biopharmaceutical company focused on the development of novel therapies to treat diseases of the brain and spinal cord. It also provides research programs to find alternative ways of treating Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, Canada. | Director/Board Member | - |
Ausbildung von Phillip Mertz
| Harvard University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ALPHA COGNITION INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Alpha Cognition, Inc. /old/
Alpha Cognition, Inc. /old/ Pharmaceuticals: MajorHealth Technology Alpha Cognition, Inc. engages in operation of a biopharmaceutical company focused on the development of novel therapies to treat diseases of the brain and spinal cord. It also provides research programs to find alternative ways of treating Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, Canada. | Health Technology |
